<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815659</url>
  </required_header>
  <id_info>
    <org_study_id>D3560L00079</org_study_id>
    <nct_id>NCT00815659</nct_id>
  </id_info>
  <brief_title>Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome</brief_title>
  <acronym>EFFORT</acronym>
  <official_title>Open-labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid
      profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol,
      triglyceride) in patients with metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Basal HDL-cholesterol Level</measure>
    <time_frame>Baseline</time_frame>
    <description>HDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL-cholesterol Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>HDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basal LDL-cholesterol Level</measure>
    <time_frame>Baseline</time_frame>
    <description>LDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL-cholesterol Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>LDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basal Total Cholesterol Level</measure>
    <time_frame>Total cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)</time_frame>
    <description>Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Cholesterol Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>Total cholesterol after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Basal Triglyceride Level</measure>
    <time_frame>Baseline</time_frame>
    <description>Triglyceride levels before (mean of visit 1 - screening and Visit 2 - enrollment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglyceride Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>Triglycerides after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Who Reached Target Level of LDL-cholesterol After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>Number of patients who reached target level of LDL-cholesterol after 3 months of rosuvastatin treatment. Target level: LDL-cholesterol: &lt;100 mg/dL; HDL-cholesterol: For males &gt;40 mg/dL, for females &gt;50 mg/dL; non-HDL-cholesterol: &lt;130 mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Who Reached Target Level of HDL-cholesterol After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>Number of patients who reached target level of HDL-cholesterol after 3 months of rosuvastatin treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients Who Reached Target Level of Non-HDL-cholesterol After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>Number of patients who reached target level of non-HDL-cholesterol after 3 months of rosuvastatin treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Basal Interleukin 1 (IL-1) Level</measure>
    <time_frame>Baseline</time_frame>
    <description>IL-1 levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 1 (IL-1) Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>IL-1 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal Interleukin 6 (IL-6) Level</measure>
    <time_frame>Baseline</time_frame>
    <description>IL-6 levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 (IL-6) Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>IL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal Interleukin 8 (IL-8) Level</measure>
    <time_frame>Baseline</time_frame>
    <description>IL-8 levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 8 (IL-8) Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>IL-8 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal Interleukin 10 (IL-10) Level</measure>
    <time_frame>Baseline</time_frame>
    <description>IL-10 levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 10 (IL-10) Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>IL-10 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal Tumor Necrosis Factor (TNF) Level</measure>
    <time_frame>Baseline</time_frame>
    <description>TNF levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis Factor (TNF) Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>TNF levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal High Sensitivity C-reactive Protein (Hs-CRP) Level</measure>
    <time_frame>Baseline</time_frame>
    <description>hs-CRP levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Sensitivity C-reactive Protein (Hs-CRP) Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>hs-CRP levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal LDL-3 Level</measure>
    <time_frame>Baseline</time_frame>
    <description>LDL subfractions are light (LDL1 and 2), intermediate (LDL3) and small dense LDL (LDL 4, 5, 6 and 7). Small dense LDL (sdLDL)-cholesterol that expresses greater atherogenicity than large buoyant LDL. Large LDL particles are the least likely to cause plaque formation, because LDL particles have to be approximately 25 nm in diameter or smaller to penetrate the artery walls. High sdLDL and decreased large HDL fraction are more common in patients with coronary heart disease than in controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-3 Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>LDL-3 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal LDL-4 Level</measure>
    <time_frame>Baseline</time_frame>
    <description>LDL-4 levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-4 Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>LDL-4 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal LDL-5 Level</measure>
    <time_frame>Baseline</time_frame>
    <description>LDL-5 levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-5 Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>LDL-5 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal LDL-6 Level</measure>
    <time_frame>Baseline</time_frame>
    <description>LDL-6 levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-6 Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>LDL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal LDL-7 Level</measure>
    <time_frame>Baseline</time_frame>
    <description>LDL-7 levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-7 Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>LDL-7 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal Large HDL Subfraction Level</measure>
    <time_frame>Baseline</time_frame>
    <description>Large HDL subfraction levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Large HDL Subfraction Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>Large HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal Intermediate HDL Subfraction Level</measure>
    <time_frame>Baseline</time_frame>
    <description>Intermediate HDL subfraction levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intermediate HDL Subfraction Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>Intermediate HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal Small HDL Subfraction Level</measure>
    <time_frame>Baseline</time_frame>
    <description>Small HDL subfraction levels before (Visit 2-enrollment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small HDL Subfraction Level After 3 Months of Rosuvastatin Treatment</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>Small HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events</measure>
    <time_frame>3 months (from enrollment to last visit)</time_frame>
    <description>Number of patients with any adverse events in 3 months of rosuvastatin treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>CRESTOR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  metabolic syndrome (according to National Cholesterol Education Program (NCEP)
             Adenosine triphosphate (ATP) Ill criteria)

          -  LDL-Cholesterol &gt; 130mg/dl

          -  HDL-Cholesterol &lt; 40mg/dl in males and &lt;50mg/dl in females

          -  Triglycerides &lt; 400 mg/dl

        Exclusion Criteria:

          -  With a concomitant coronary disease

          -  Currently under statin therapy or previously treated with statins within the last 6
             months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dilek Ural, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kocaeli University Faculty of Medicine Cardiology Dept</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ankara</city>
        <state>Besevler</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kayseri</city>
        <state>Erciyes</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Istanbul</city>
        <state>Haseki</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kocaeli</city>
        <state>Umuttepe</state>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2008</study_first_submitted>
  <study_first_submitted_qc>December 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2008</study_first_posted>
  <results_first_submitted>March 24, 2011</results_first_submitted>
  <results_first_submitted_qc>June 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2011</results_first_posted>
  <last_update_submitted>August 29, 2011</last_update_submitted>
  <last_update_submitted_qc>August 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plasma lipid profile</keyword>
  <keyword>metabolic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Crestor</title>
          <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Crestor</title>
          <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Basal HDL-cholesterol Level</title>
        <description>HDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal HDL-cholesterol Level</title>
          <description>HDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>HDL-cholesterol Level After 3 Months of Rosuvastatin Treatment</title>
        <description>HDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) HDL levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>HDL-cholesterol Level After 3 Months of Rosuvastatin Treatment</title>
          <description>HDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) HDL levels of participants</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Basal LDL-cholesterol Level</title>
        <description>LDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline LDL levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal LDL-cholesterol Level</title>
          <description>LDL-cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)</description>
          <population>Baseline LDL levels of participants</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.5" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LDL-cholesterol Level After 3 Months of Rosuvastatin Treatment</title>
        <description>LDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) LDL levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-cholesterol Level After 3 Months of Rosuvastatin Treatment</title>
          <description>LDL- cholesterol levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) LDL levels of participants</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" spread="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Basal Total Cholesterol Level</title>
        <description>Baseline</description>
        <time_frame>Total cholesterol levels before (mean of visit 1 - screening and Visit 2 - enrollment)</time_frame>
        <population>Baseline total cholesterol levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal Total Cholesterol Level</title>
          <description>Baseline</description>
          <population>Baseline total cholesterol levels of participants</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236.5" spread="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Cholesterol Level After 3 Months of Rosuvastatin Treatment</title>
        <description>Total cholesterol after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) total cholesterol levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol Level After 3 Months of Rosuvastatin Treatment</title>
          <description>Total cholesterol after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) total cholesterol levels of participants</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.2" spread="47.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Basal Triglyceride Level</title>
        <description>Triglyceride levels before (mean of visit 1 - screening and Visit 2 - enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline triglyceride levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal Triglyceride Level</title>
          <description>Triglyceride levels before (mean of visit 1 - screening and Visit 2 - enrollment)</description>
          <population>Baseline triglyceride levels of participants</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.1" spread="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Triglyceride Level After 3 Months of Rosuvastatin Treatment</title>
        <description>Triglycerides after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) triglyceride levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride Level After 3 Months of Rosuvastatin Treatment</title>
          <description>Triglycerides after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) triglyceride levels of participants</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153.1" spread="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Reached Target Level of LDL-cholesterol After 3 Months of Rosuvastatin Treatment</title>
        <description>Number of patients who reached target level of LDL-cholesterol after 3 months of rosuvastatin treatment. Target level: LDL-cholesterol: &lt;100 mg/dL; HDL-cholesterol: For males &gt;40 mg/dL, for females &gt;50 mg/dL; non-HDL-cholesterol: &lt;130 mg/dL</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LDL cholesterol levels &lt; 100 mg/dL, calculated over patients with lipid measurement performed at both visits</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reached Target Level of LDL-cholesterol After 3 Months of Rosuvastatin Treatment</title>
          <description>Number of patients who reached target level of LDL-cholesterol after 3 months of rosuvastatin treatment. Target level: LDL-cholesterol: &lt;100 mg/dL; HDL-cholesterol: For males &gt;40 mg/dL, for females &gt;50 mg/dL; non-HDL-cholesterol: &lt;130 mg/dL</description>
          <population>LDL cholesterol levels &lt; 100 mg/dL, calculated over patients with lipid measurement performed at both visits</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Reached Target Level of HDL-cholesterol After 3 Months of Rosuvastatin Treatment</title>
        <description>Number of patients who reached target level of HDL-cholesterol after 3 months of rosuvastatin treatment</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>HDL cholesterol target levels for males &gt;40 mg/dL, for females &gt; 50 mg/dL, calculated over patients with lipid measurement performed at both visits</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reached Target Level of HDL-cholesterol After 3 Months of Rosuvastatin Treatment</title>
          <description>Number of patients who reached target level of HDL-cholesterol after 3 months of rosuvastatin treatment</description>
          <population>HDL cholesterol target levels for males &gt;40 mg/dL, for females &gt; 50 mg/dL, calculated over patients with lipid measurement performed at both visits</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Reached Target Level of Non-HDL-cholesterol After 3 Months of Rosuvastatin Treatment</title>
        <description>Number of patients who reached target level of non-HDL-cholesterol after 3 months of rosuvastatin treatment</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>Non-HDL cholesterol target levels &lt;130 mg/dL, calculated over patients with lipid measurement performed at both visits</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reached Target Level of Non-HDL-cholesterol After 3 Months of Rosuvastatin Treatment</title>
          <description>Number of patients who reached target level of non-HDL-cholesterol after 3 months of rosuvastatin treatment</description>
          <population>Non-HDL cholesterol target levels &lt;130 mg/dL, calculated over patients with lipid measurement performed at both visits</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal Interleukin 1 (IL-1) Level</title>
        <description>IL-1 levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline IL-1 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal Interleukin 1 (IL-1) Level</title>
          <description>IL-1 levels before (Visit 2-enrollment)</description>
          <population>Baseline IL-1 levels of participants</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 1 (IL-1) Level After 3 Months of Rosuvastatin Treatment</title>
        <description>IL-1 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) IL-1 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 1 (IL-1) Level After 3 Months of Rosuvastatin Treatment</title>
          <description>IL-1 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) IL-1 levels of participants</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal Interleukin 6 (IL-6) Level</title>
        <description>IL-6 levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline IL-6 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal Interleukin 6 (IL-6) Level</title>
          <description>IL-6 levels before (Visit 2-enrollment)</description>
          <population>Baseline IL-6 levels of participants</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 6 (IL-6) Level After 3 Months of Rosuvastatin Treatment</title>
        <description>IL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) IL-6 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 6 (IL-6) Level After 3 Months of Rosuvastatin Treatment</title>
          <description>IL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) IL-6 levels of participants</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal Interleukin 8 (IL-8) Level</title>
        <description>IL-8 levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline IL-8 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal Interleukin 8 (IL-8) Level</title>
          <description>IL-8 levels before (Visit 2-enrollment)</description>
          <population>Baseline IL-8 levels of participants</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 8 (IL-8) Level After 3 Months of Rosuvastatin Treatment</title>
        <description>IL-8 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) IL-8 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 8 (IL-8) Level After 3 Months of Rosuvastatin Treatment</title>
          <description>IL-8 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) IL-8 levels of participants</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal Interleukin 10 (IL-10) Level</title>
        <description>IL-10 levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline IL-10 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal Interleukin 10 (IL-10) Level</title>
          <description>IL-10 levels before (Visit 2-enrollment)</description>
          <population>Baseline IL-10 levels of participants</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Interleukin 10 (IL-10) Level After 3 Months of Rosuvastatin Treatment</title>
        <description>IL-10 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) IL-10 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 10 (IL-10) Level After 3 Months of Rosuvastatin Treatment</title>
          <description>IL-10 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) IL-10 levels of participants</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal Tumor Necrosis Factor (TNF) Level</title>
        <description>TNF levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline Basal Tumor Necrosis Factor (TNF) levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal Tumor Necrosis Factor (TNF) Level</title>
          <description>TNF levels before (Visit 2-enrollment)</description>
          <population>Baseline Basal Tumor Necrosis Factor (TNF) levels of participants</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Necrosis Factor (TNF) Level After 3 Months of Rosuvastatin Treatment</title>
        <description>TNF levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) Tumor Necrosis Factor (TNF) levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Necrosis Factor (TNF) Level After 3 Months of Rosuvastatin Treatment</title>
          <description>TNF levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) Tumor Necrosis Factor (TNF) levels of participants</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal High Sensitivity C-reactive Protein (Hs-CRP) Level</title>
        <description>hs-CRP levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline High Sensitivity C-reactive protein (Hs-CRP) levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal High Sensitivity C-reactive Protein (Hs-CRP) Level</title>
          <description>hs-CRP levels before (Visit 2-enrollment)</description>
          <population>Baseline High Sensitivity C-reactive protein (Hs-CRP) levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Sensitivity C-reactive Protein (Hs-CRP) Level After 3 Months of Rosuvastatin Treatment</title>
        <description>hs-CRP levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) High Sensitivity C-reactive protein (Hs-CRP) levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>High Sensitivity C-reactive Protein (Hs-CRP) Level After 3 Months of Rosuvastatin Treatment</title>
          <description>hs-CRP levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) High Sensitivity C-reactive protein (Hs-CRP) levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal LDL-3 Level</title>
        <description>LDL subfractions are light (LDL1 and 2), intermediate (LDL3) and small dense LDL (LDL 4, 5, 6 and 7). Small dense LDL (sdLDL)-cholesterol that expresses greater atherogenicity than large buoyant LDL. Large LDL particles are the least likely to cause plaque formation, because LDL particles have to be approximately 25 nm in diameter or smaller to penetrate the artery walls. High sdLDL and decreased large HDL fraction are more common in patients with coronary heart disease than in controls</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline LDL-3 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal LDL-3 Level</title>
          <description>LDL subfractions are light (LDL1 and 2), intermediate (LDL3) and small dense LDL (LDL 4, 5, 6 and 7). Small dense LDL (sdLDL)-cholesterol that expresses greater atherogenicity than large buoyant LDL. Large LDL particles are the least likely to cause plaque formation, because LDL particles have to be approximately 25 nm in diameter or smaller to penetrate the artery walls. High sdLDL and decreased large HDL fraction are more common in patients with coronary heart disease than in controls</description>
          <population>Baseline LDL-3 levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL-3 Level After 3 Months of Rosuvastatin Treatment</title>
        <description>LDL-3 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) LDL-3 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-3 Level After 3 Months of Rosuvastatin Treatment</title>
          <description>LDL-3 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) LDL-3 levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal LDL-4 Level</title>
        <description>LDL-4 levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline LDL-4 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal LDL-4 Level</title>
          <description>LDL-4 levels before (Visit 2-enrollment)</description>
          <population>Baseline LDL-4 levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL-4 Level After 3 Months of Rosuvastatin Treatment</title>
        <description>LDL-4 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF(Last Observation Carried Forward) LDL-4 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-4 Level After 3 Months of Rosuvastatin Treatment</title>
          <description>LDL-4 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF(Last Observation Carried Forward) LDL-4 levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal LDL-5 Level</title>
        <description>LDL-5 levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline LDL-5 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal LDL-5 Level</title>
          <description>LDL-5 levels before (Visit 2-enrollment)</description>
          <population>Baseline LDL-5 levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL-5 Level After 3 Months of Rosuvastatin Treatment</title>
        <description>LDL-5 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) LDL-5 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-5 Level After 3 Months of Rosuvastatin Treatment</title>
          <description>LDL-5 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) LDL-5 levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal LDL-6 Level</title>
        <description>LDL-6 levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline LDL-6 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal LDL-6 Level</title>
          <description>LDL-6 levels before (Visit 2-enrollment)</description>
          <population>Baseline LDL-6 levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL-6 Level After 3 Months of Rosuvastatin Treatment</title>
        <description>LDL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) LDL-6 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-6 Level After 3 Months of Rosuvastatin Treatment</title>
          <description>LDL-6 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) LDL-6 levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal LDL-7 Level</title>
        <description>LDL-7 levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline LDL-7 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal LDL-7 Level</title>
          <description>LDL-7 levels before (Visit 2-enrollment)</description>
          <population>Baseline LDL-7 levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL-7 Level After 3 Months of Rosuvastatin Treatment</title>
        <description>LDL-7 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) LDL-7 levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-7 Level After 3 Months of Rosuvastatin Treatment</title>
          <description>LDL-7 levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) LDL-7 levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal Large HDL Subfraction Level</title>
        <description>Large HDL subfraction levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline Large HDL subfraction of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal Large HDL Subfraction Level</title>
          <description>Large HDL subfraction levels before (Visit 2-enrollment)</description>
          <population>Baseline Large HDL subfraction of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Large HDL Subfraction Level After 3 Months of Rosuvastatin Treatment</title>
        <description>Large HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) Large HDL subfraction levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Large HDL Subfraction Level After 3 Months of Rosuvastatin Treatment</title>
          <description>Large HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) Large HDL subfraction levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal Intermediate HDL Subfraction Level</title>
        <description>Intermediate HDL subfraction levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline Intermediate HDL subfraction of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal Intermediate HDL Subfraction Level</title>
          <description>Intermediate HDL subfraction levels before (Visit 2-enrollment)</description>
          <population>Baseline Intermediate HDL subfraction of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intermediate HDL Subfraction Level After 3 Months of Rosuvastatin Treatment</title>
        <description>Intermediate HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) Intermediate HDL subfraction levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Intermediate HDL Subfraction Level After 3 Months of Rosuvastatin Treatment</title>
          <description>Intermediate HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) Intermediate HDL subfraction levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal Small HDL Subfraction Level</title>
        <description>Small HDL subfraction levels before (Visit 2-enrollment)</description>
        <time_frame>Baseline</time_frame>
        <population>Baseline Small HDL subfraction of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Basal Small HDL Subfraction Level</title>
          <description>Small HDL subfraction levels before (Visit 2-enrollment)</description>
          <population>Baseline Small HDL subfraction of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Small HDL Subfraction Level After 3 Months of Rosuvastatin Treatment</title>
        <description>Small HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>LOCF (Last Observation Carried Forward) Small HDL subfraction levels of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Small HDL Subfraction Level After 3 Months of Rosuvastatin Treatment</title>
          <description>Small HDL subfraction levels after 3 months of rosuvastatin treatment (last observation carried forward; LOCF)</description>
          <population>LOCF (Last Observation Carried Forward) Small HDL subfraction levels of participants</population>
          <units>mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events</title>
        <description>Number of patients with any adverse events in 3 months of rosuvastatin treatment</description>
        <time_frame>3 months (from enrollment to last visit)</time_frame>
        <population>Number of patients with any adverse events in 3 months</population>
        <group_list>
          <group group_id="O1">
            <title>Crestor</title>
            <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events</title>
          <description>Number of patients with any adverse events in 3 months of rosuvastatin treatment</description>
          <population>Number of patients with any adverse events in 3 months</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Crestor</title>
          <description>Rosuvastatin 10 mg/day for 6 weeks, then 20 mg/day for 6 more weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Twitching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Liver Function Tests Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Acute Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>CK Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Leg Cramp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Leg Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough-Dry Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus-Allergy-Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Dermatoid</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

